JLL to buy more CMOs; Regeneron nabs an approval in Japan for Eylea; Soros buys up Teva shares;

@FiercePharma: Thursday's best-read special report: Top 10 Patent Losses of 2014. Report | Follow @FiercePharma

@EricPFierce: Pfizer says it will close a Puerto Rico plant days after Merck says the same thing. Story | Follow @EricPFierce

@CarlyHFierce: Biogen Idec's MS pill Tecfidera wins 10 years' protection in EU. Analysts expect 36% of $4.5B in 2018 sales to come from non-U.S. More | Follow @CarlyHFierce

> Paul Levy, cofounder of JLL Partners, says he expects the company to buy more contract manufacturers as a follow-up to its $2.6 billion deal to buy the pharmaceutical unit of Dutch-based Royal DSM and combine it with CMO Patheon. Story

> Regeneron Pharmaceuticals ($REGN) said Japan has approved Eylea for the treatment of macular edema following central retinal vein occlusion (CRVO). Story

> GlaxoSmithKline ($GSK) has announced a plant expansion in Scotland that will add 25 jobs when complete. Story

> In more bad news for Amarin ($AMRN), its said the FDA will not consider its appeal of its regulatory decision to revoke an agreement related to the trial of Vascepa. Story

> Soros Fund Management, the investment vehicle for billionaire George Soros, has upped its stake in Teva Pharmaceutical Industries ($TEVA), which has been floundering in the wake of letting its CEO go. Story  

> India's Biocon has gotten approval from the Indian drug regulator to produce a biosimilar version of Roche's ($RHHBY) blockbuster Herceptin. Story

Medical Device News

@FierceMedDev: Myriad partners up with BioMarin for cancer diagnostics. Yesterday's story | Follow @FierceMedDev

@MarkHFierce: OraSure dumped Roche in favor of Thermo Fisher for a drug testing Dx development deal. Strategic, not fickle. Yesterday's story | Follow @MarkHFierce

@MichaelGFierce: FDA allows pivotal trial of Actinium's armed-antibody isotope delivery. More from FierceDrugDelivery | Follow @MichaelGFierce

> Covidien plans $18M Florida expansion as it cuts and reorganizes elsewhere. Story

> Cyberonics shares climb again after fruitful Q2. Article

> J&J now mulling three bids for Ortho Clinical Dx division. More

> Judge cautions that unscrupulous attorneys may exploit J&J hip settlement. Item

Biotech News

@FierceBiotech: Avalon jumpstarts first biotech in $500M GlaxoSmithKline portfolio deal. Article | Follow @FierceBiotech

@JohnCFierce: Lots of biotech startup news this month. Lots of deal flow in the pipeline. | Follow @JohnCFierce

@DamianFierce: Meet LEE011, Novartis's overnight celebrity breast cancer candidate. News | Follow @DamianFierce

@EmilyMFierce: Eli Lilly, Project A.L.S. forge preclinical drug discovery pact. Story | Follow @EmilyMFierce

> Regeneron, Sanofi hit a trio of goals in first PhIII test of rheumatoid arthritis drug. Story

> Novartis sneaks up on Pfizer with CDK4/6 cancer challenger. Article

> Food allergy startup bags $17M for oral immunotherapy. News

And Finally... Merck ($MRK), pointing to the high maternal death rate in the U.S., is bringing its Merck for Mothers, a program designed to help reduce maternal deaths tied to pregnancy that it created for developing countries, to the U.S. Release

Suggested Articles

After years of having first-line liver cancer market to itself, Bayer’s Nexavar is getting major competition from Roche's Tecentriq.

Most of the recent enthusiasm around AbbVie’s new drugs has centered on Skyrizi and Rinvoq, but elagolix wants a piece of the spotlight, too.

During David Loew's tenure, Sanofi Pasteur bought Protein Sciences, whose recombinant technology is being applied to a COVID-19 vaccine.